Data on retreatment experiences with brentuximab vedotin in clinical trials to be presented at 2010 ASCO

Data on retreatment experiences with brentuximab vedotin in clinical trials to be presented at 2010 ASCO
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company today announced that data regarding retreatment experiences with brentuximab vedotin in phase I and phase II clinical trials will be presented during a poster session at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8, 2010 in Chicago, Illinois.

Read more on News-Medical-Net

More Meth Drug Addiction Info:

• Asco Auto cutting table for roller blinds | ytlsf blog
• Sunesis (SNSS): Elderly AML ASCO Abstract Quick Rundown » GekkoWire
• Takeda; When Bad Recommendations Go Good, Part Two | A New Band A Day!
• Skymark Research Initiates Independent Research Coverage on …
• New Data From Lilly Oncology Pipeline To Be Presented At ASCO 2010 …
• Psychology Department presents Research Conference poster session …
• Seattle Genetics and Millennium to Present Brentuximab Vedotin …
• Nexavar Data to be Presented at 46th American Society of Clinical …
• ! Tips Amgen Highlights Key Clinical Data To Be Presented At …
• Drugs and Diseases » Blog Archive » ASCO presentation further …